ClinicalTrials.gg
RecruitingNCT07140601CLEANUpdated Aug 24, 2025

Environmental Pollutants and Neurological Disorders

An observational study in Cerebrovascular Disorders, Brain Tumours and Alzheimer Dementia, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Beijing Tiantan Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, 1 of them phase 3. Cerebrovascular Disorders · Beijing Tiantan Hospital.

Started
2025
with 4 others
Observational
5 of 12
5 open now
Registered
12th of 12
by date

Among the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital, this one is one of 5 that started in 2025, is one of 5 observational ones, and was the 12th registered.

Cerebrovascular Disorders

450 studies on the registry are indexed under Cerebrovascular Disorders; 126 are open to participants now.

Browse Cerebrovascular Disorders studies →

Open to participants now

10 of the 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 94 Cerebrovascular Disorders studies recruiting now, 54 (57%) set no upper age limit and 12 (13%) stop at 75 or younger; 10 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cerebrovascular Disorders by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including micro- and nanoplastics, per- and polyfluoroalkyl substances (PFAS), antibiotics, and endocrine-disrupting chemicals-to adverse neurological outcomes. These pollutants can cross or disrupt the blood-brain barrier, accumulate in neural tissue, and trigger oxidative stress, inflammation, epigenetic modifications, and metabolic reprogramming.

Brain tumours and cerebrovascular diseases represent two major categories of neurosurgical disorders with high morbidity and mortality. However, their interaction with environmental pollutant exposure remains poorly understood. Recent studies suggest that pollutant-induced molecular alterations, such as aberrant DNA methylation, lipid metabolism disruption, and neurovascular endothelial dysfunction, may contribute to tumour initiation, malignant progression, aneurysm formation, and stroke occurrence.

Given the increasing human exposure to these pollutants and the lack of large-scale clinical data, it is urgent to establish a systematic investigation in neurosurgical patients. This study aims to profile pollutant exposure (heavy metals, PFAS, microplastics, and other novel contaminants) using multi-biospecimen analysis (blood, urine, hair, tumour and peri-tumour tissues), and to explore their mechanistic links to the pathogenesis of brain tumours and cerebrovascular diseases. The findings are expected to provide new evidence for understanding environment-brain interactions and to identify potential biomarkers for disease risk stratification and prevention.

03

Conditions studied

  • Cerebrovascular Disorders
  • Brain Tumours
  • Alzheimer Dementia

Keywords

  • Environmental Pollutants
  • Exposomics
  • Pathogenic Mechanisms
  • Neurological Disorders
  • Neurosurgical Patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with brain tumours or cerebrovascular diseases who need surgical resection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older;
  • Able to give to participate in the research.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate.
  • Pregnant or breastfeeding woman.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the sample collection date to death due to any cause. All other participants will be censored at the last date known to be alive.

    Time frame: Until death or study completion (24 months)

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the duration of time from sample collection date to time of progression or death, whichever occurs first.

    Time frame: Until progression or death or study completion (24 months)

  2. modified Rankin Scale (mRS)

    Patients' mRS scores at 90 days after sample collection.

    Time frame: 90 days after sample collection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.

Of 77 non-industry observational studies under Cerebrovascular Disorders, half reached primary completion within 103 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 339. This study's planned 4 months is below that.

Counting every sponsor, half of 81 studies reached it within 101 months; a quarter within 57 and three quarters within 339.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 24, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Aug 1, 2027
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07140601
Collaborators
Chinese Research Academy of Environmental Sciences, Nanjing University, Nanjing Institute of Environmental Sciences, Chinese Academy of Environmental Planning, Peking Union Medical College, National Human Brain Bank for Development and Function
Responsible party
Xiaolin Chen, MD (Prof., Beijing Tiantan Hospital) — Principal investigator
First posted
Aug 24, 2025
Start date
Aug 1, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Aug 24, 2025

Study contacts

Runting Li, MD
Contact
tt18080lrt@163.com
+86 15753166690

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion